Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
62 (26%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-RIZATRIPTAN | 10MG | TABLET | Resolved | 2017-03-11 | 2017-08-18 | 504 |
| APO-RIZATRIPTAN | 10MG | TABLET | Resolved | 2025-04-04 | 2025-04-11 | 254169 |
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2025-01-16 | 2025-01-24 | 247859 |
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2017-07-04 | 2018-01-10 | 14560 |
| APO-RIZATRIPTAN | 10MG | TABLET | Resolved | 2024-08-22 | 2024-11-22 | 235698 |
| APO-RIZATRIPTAN | 10MG | TABLET | Resolved | 2024-12-12 | 2025-01-24 | 245511 |
| APO-RIZATRIPTAN | 10MG | TABLET | Resolved | 2022-08-11 | 2022-10-14 | 166439 |
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2022-09-09 | 2022-10-14 | 169057 |
| APO-RIZATRIPTAN | 10MG | TABLET | Resolved | 2018-02-05 | 2019-05-06 | 38491 |
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2021-09-17 | 2021-11-08 | 145843 |
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2023-06-23 | 2023-06-29 | 196303 |
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2018-11-16 | 2019-05-06 | 67031 |
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2020-07-08 | 2020-08-21 | 119770 |
| APO-RIZATRIPTAN RPD | 10MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2017-03-11 | 2020-07-06 | 490 |
| APO-RIZATRIPTAN RPD | 5MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2017-03-11 | 2018-09-11 | 493 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-03-12 | 2017-03-31 | 725 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-04-24 | 2017-06-13 | 7716 |
| APO-ROSUVASTATIN | 10MG | TABLET | Resolved | 2017-05-02 | 2017-08-16 | 8710 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2017-05-02 | 2017-08-17 | 8713 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2019-12-18 | 2020-03-09 | 101517 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |